Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure

Author:

Erland Erdmann1,Philippe Lechat2,Patricia Verkenne3,Hermann Wiemann3

Affiliation:

1. University of Cologne; Joseph-Stelzmann-Str. 9 50924 Cologne Germany

2. Hôpital Pitié Salpétrière; 47, Boulevard de l'Hôpital F-75651 Paris Cedex 13 France

3. Merck KGaA; Frankfurter Str. 250 D-64271 Darmstradt Germany

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. A rationale for the use of β-blockers as standard treatment for heart failure;Metra;Am Heart J,2000

2. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure;Eichhorn;Circulation,1996

3. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure;Eichorn;Am J Cardiol,1999

4. Rationale for treatment of patients with chronic heart failure with adrenergic blockade;Sackner-Bernstein;J Am Med Assoc,1995

5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial;CIBIS II Investigators and Committess;Lancet,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3